Ovarian Cancer Industry Council

As the leading ovarian cancer organization in the world, we recognize that our goal of curing this disease requires stakeholder collaboration on all fronts to ensure the expedient development of safe and beneficial therapies. In support of our mission, we engage in collaborations with partners in the pharmaceutical, biomedical and diagnostic industries to advance the science, enhance clinical research and ensure patient-centric development of effective treatments and diagnostic methods.  

First convened in January 2021, the Industry Council prioritizes topics of interest to all stakeholders in the field, facilitates the sharing of insights and ideas, and advances cross-sector engagement. The Council is comprised of patients, advocates, clinicians, investigators, federal regulators and industry all collaborating to identify tangible action steps.

Through the work of the Council, members collaborate to address community challenges and accomplish mutually beneficial goals with OCRA leadership, clinical experts and prominent scientists. The Council addresses specific issues; from lessons learned, to challenges, to potential solutions and concrete action steps with the overarching goal of improving outcomes for the ovarian cancer community, and ultimately, to find a cure.  

Previous Ovarian Cancer Industry Council meeting topics and goals:

  • July 2022: Patient Perspectives and Dose Optimization
    On July 13, 2022, Ovarian Cancer Research Alliance (OCRA) convened an Industry Council discussion among approximately 30 ovarian cancer stakeholders about dosing, safety, and tolerability aspects of therapies for ovarian cancer, with a specific focus on perspectives of ovarian cancer patients. Dr. Vishal Bhatnagar, FDA OCE, described efforts at FDA to capture and disseminate patient-generated information about the patient experience with oncology drugs in development through Project Patient Voice. Dr. Mirat Shah, FDA OCE, described Project Optimus, an initiative to reform the dose optimization and dose selection paradigm in oncology drug development.  
  • March 2022: Biobank/ Data Sharing Discussion
    Engaged approximately 30 ovarian cancer stakeholders focused on the potential to advance a biobank/ data commons project for ovarian cancer in the U.S. Stakeholders from global academic institutions, government regulatory bodies, the pharmaceutical industry and patient advocates provided input to OCRA about the need and potential structure for an ovarian cancer biobank or biospecimen/ data-sharing mechanism to facilitate research collaborations and advance development of new therapies.
  • October 2021: Lessons Learned, Challenges, and Opportunities for Advancing Precision Medicine in Ovarian Cancer
    Evaluated opportunities and discuss challenges in precision medicine and biomarker development for ovarian cancer. Discussed lessons learned and current gaps to be addressed in research and clinical trials specific to biomarkers, including assay development, clinical trial design, and regulatory processes.
  • April 2021, May 2021: Collaborating to Enhance Accrual and Expand Diversity for Ovarian Cancer Clinical Trials
    Evaluated barriers to ovarian cancer clinical trial accrual and diversity within ovarian cancer clinical trials. Identified multi-stakeholder solutions to enhance accrual and expand diversity in ovarian cancer clinical trials.
  • August 2020: The Impact of COVID-19 on the Ovarian Cancer Community
    Presented findings of a patient survey on barriers to care, conducted by OCRA. Evaluated access issues and solutions in reducing barriers to care. 

To learn more about how OCRA collaborates with industry partners, please view our Conflict of Interest Statement.

Founding Members

Conflict of Interest Statement — Industry Partners

  • Corporate partners including industry do not shape OCRA’s agenda, research or advocacy.
  • In 2021, industry partners represented 11% of OCRA’s overall revenue.
  • No industry personnel serve on OCRA’s governing board (Board of Directors).
  • If an industry partner sponsors an OCRA program, grant or educational materials, it is publicly acknowledged and the supporting company has no editorial or strategic input. 
  • Any reference to a specific commercial product or service does not constitute or imply an endorsement by OCRA of the product or service or its producer or provider. The views and opinions expressed in any referenced document or on any referenced website do not necessarily reflect those of OCRA.
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]